Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:51:12.245Z.
Calculation as of: 2026-10-06T15:51:12.245Z.
Quote observation: 2026-10-06T15:49:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dda5353817af794375b978a2faa289dfa66a026ad884c07a98b38d1ad02c68b2
PE RATIO
N/A
Market Cap
$103.68M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.08M
PE Ratio
N/A
TTM Avg
2144.18
3Y Avg
993.27
5Y Avg
551.35
Market Cap
$108.67M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.16M
PE Ratio
N/A
TTM Avg
17.69
3Y Avg
17.69
5Y Avg
17.69
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definitive Healthcare Corp. (DH) | $105.51M | N/A | N/A | N/A | N/A |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $103.68M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.08M | N/A | 2144.18 | 993.27 | 551.35 |
| Anixa Biosciences, Inc. (ANIX)vs › | $103.60M | N/A | 597.78 | 597.78 | 597.78 |
| The Joint Corp. (JYNT)vs › | $103.14M | 27.29 | 39.41 | 48.57 | 115.64 |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.86M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.67M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $109.16M | N/A | 17.69 | 17.69 | 17.69 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $109.19M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $110.67M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
5.1
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.00
Forward EPS (Est.)
$0.19
Forward P/E
5.14
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
